Valuation: C4 Therapeutics, Inc.

Market Cap 475M 416M 382M 356M 675M 45.27B 686M 4.59B 1.78B 22.25B 1.78B 1.75B 76.68B P/E 2026 *
-4.6x
P/E 2027 * -4.27x
Enterprise Value 475M 416M 382M 356M 675M 45.27B 686M 4.59B 1.78B 22.25B 1.78B 1.75B 76.68B EV / Sales 2026 *
25.1x
EV / Sales 2027 * 24.8x
Free-Float
99.08%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: C4 Therapeutics, Inc.

1 day-0.92%
1 week-2.27%
Current month-7.92%
1 month-0.92%
3 months+52.48%
6 months+122.80%
Current year+125.13%
1 week 4.12
Extreme 4.125
5.17
1 month 3.44
Extreme 3.44
5.17
Current year 1.69
Extreme 1.6901
5.17
1 year 1.44
Extreme 1.44
5.17
3 years 1.06
Extreme 1.06
11.88
5 years 1.06
Extreme 1.06
51.21
10 years 1.06
Extreme 1.06
51.21
Manager TitleAgeSince
Chief Executive Officer 55 2020-10-01
Director of Finance/CFO 49 2023-09-17
Chief Tech/Sci/R&D Officer 56 2024-10-27
Director TitleAgeSince
Director/Board Member 74 2015-11-30
Director/Board Member 55 2020-09-13
Director/Board Member 55 2022-03-15
Date Insider Type Main position Quantity % Market Cap.
06-23Free

Founder

62,000 0.0561%
06-23Free

Chairman

62,000 0.0561%
06-23Free

Director

62,000 0.0561%
Change 5-day change 1-year change 3-year change Capi.($)
-0.92%-2.27%+182.89%+56.36% 475M
+1.70%+6.73%+2.48%+7.78% 49.15B
+0.92%+6.21%+408.85%+607.44% 40.23B
+1.89%+11.06%+25.75%-7.89% 34.55B
+5.46%+8.10%+21.83%+66.94% 33.09B
+3.96%+6.07%+14.14%+37.68% 25.19B
+2.51%+4.94% - - 17.05B
+2.58%+7.24%+71.03%+132.17% 15.92B
+0.32%+0.35%+13.41%+18.82% 13.83B
-1.14%+7.52%+14.75%-30.83% 13.26B
Average +1.36%+4.29%+83.90%+98.72% 24.27B
Weighted average by Cap. +1.72%+5.25%+89.22%+131.57%

Financials

2026 *2027 *
Net sales 18.92M 16.54M 15.2M 14.17M 26.88M 1.8B 27.29M 183M 70.96M 886M 71.04M 69.51M 3.05B 19.14M 16.73M 15.38M 14.33M 27.19M 1.82B 27.6M 185M 71.76M 896M 71.84M 70.3M 3.09B
Net income -119M -104M -95.75M -89.25M -169M -11.35B -172M -1.15B -447M -5.58B -447M -438M -19.22B -151M -132M -121M -113M -214M -14.35B -217M -1.45B -565M -7.05B -566M -554M -24.31B
Net Debt - -
Logo C4 Therapeutics, Inc.
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on delivering targeted protein degradation science to create a new generation of medicines that transform patients’ lives. The Company is focused on progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to design and optimize small-molecule medicines to address difficult-to-treat diseases. Its advanced product candidate, cemsidomide, is an orally bioavailable MonoDAC degrader of protein targets called IKZF1 and IKZF3. Cemsidomide is in clinical development for multiple myeloma (MM), and non-Hodgkin lymphoma (NHL). Its CFT1946 is an orally bioavailable BiDAC degrader designed to be potent and selective against BRAF V600X mutant proteins. It is also developing CFT8919, an orally bioavailable, allosteric, mutant-selective BiDAC degrader of epidermal growth factor receptor (EGFR), with an L858R mutation in non-small lung cancer (NSCLC).
Employees
104
Date Price Change Volume
26-07-02 US$4.300 -0.92% 2,624,634
26-07-01 US$4.340 -7.07% 5,353,038
26-06-30 US$4.670 +7.36% 6,615,880
26-06-29 US$4.350 +2.11% 3,120,878
26-06-26 US$4.260 -3.18% 20,144,416
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
4.300USD
Average target price
13.33USD
Spread / Average Target
+210.08%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CCCC Stock